timothy sykes logo
Inspire Medical Systems Stock Soars on Strong Q3 Results and Favorable Forecasts Thumbnail
ADD US ONG Google News

Inspire Medical Systems Stock Soars on Strong Q3 Results and Favorable Forecasts

MATT MONACO•UPDATED NOV. 22, 2025, 8:14 AM ET
Reviewed by Jack Kellogg Fact-checked by Tim Sykes

Inspire Medical Systems Inc. stocks have been trading up by 8.51 percent following positive news on promising new treatments.

Healthcare industry expert:

Analyst sentiment – neutral

Inspire Medical Systems (INSP) demonstrates strong market fundamentals with an impressive gross margin of 84.5%, significantly higher than industry averages. However, the company exhibits a negative pre-tax profit margin of -2.5% and return on assets at -2.69%, indicating some inefficiencies. Despite a lack of dividend payments, the company’s total debt to equity ratio is exceptionally low at 0.05, evidencing robust financial stability. Revenue growth is evident with a 60.33% increase over five years. Management effectiveness, particularly return on capital at -7.07%, poses concerns about long-term sustainable profitability.

Analyzing the recent weekly price patterns, Inspire Medical’s stock shows volatility with a recent spike, closing at $90.36 after a week opening at $84.87. The upward price action confirms a bullish trend with momentum gaining post-earnings release. Candlestick patterns depict steadily increasing lows, accompanied by strong volume, supporting further increases. Traders should consider a buying strategy at support levels around $83 with a target of $95, anticipating continued upward momentum. The 5-minute candlestick analysis confirms sustained buying interest at higher price levels.

Recent corporate developments substantially boost Inspire Medical’s

Candlestick Chart

Weekly Update Nov 17 – Nov 21, 2025: On Saturday, November 22, 2025 Inspire Medical Systems Inc. stock [NYSE: INSP] is trending up by 8.51%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Inspire Medical Systems Inc.’s recent financial performance showcased a notable uptick, with Q3 figures surpassing expectations. The company realized robust revenue growth of $224.5M, which went beyond the analyst forecast by $4.1M. The transition to the Inspire V system delivered measurable enhancement in their clinical efficacy. Inspirationally, reported earnings per share catapulted to 38 cents, remarkably surpassing the predicted loss of 17 cents.

The company’s profitability metrics show stability. It maintained an impressive gross margin of 84.5%. Although their total expenses stood at $214.9M, their profit margin cont was a healthy 6.17%. Key ratios, such as a price-to-book ratio of 3.57 and a current ratio of 6.1, demonstrate their financial soundness and liquidity ease. Estimations on revenues reveal a promising picture, with revenue forecasts for 2026 projecting a 10% to 11% increase, albeit slightly below consensus hopes of 14%.

More Breaking News

Stock chart analysis indicates a positive momentum with stock price increments to $90.36 on November 21. This price shift mirrors investor confidence, fueled further by reports of a significant income tax benefit averaging around $100M. Financially strategic maneuvers, such as their tax allowances, have the potential to augment the diluted EPS by over $3.00. The company’s efficient capital allocation strategies and cash flow optimization remain focal points, indicative of their well-considered governance approach.

Conclusion

In summary, Inspire Medical Systems Inc.’s recent financial disclosures and market updates paint a vivid picture of a company effectively navigating industry dynamics while delivering substantial shareholder value. When considering stock trading, it is essential to remember what millionaire penny stock trader and teacher Tim Sykes says, “Consistency is key in trading; don’t let emotions dictate your trades.” Their efficient leveraging of available tax allowances, combined with an adept operational approach and progressive financial improvements, spotlight the company’s potential for continued upward movement in stock value. With reinforced confidence stemming from strategic trader partnerships and aligned forecasts, Inspire Medical Systems appears poised for resilient growth and market validation, well-positioned moving into the upcoming fiscal periods.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading INSP

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”